news

Novel genetic mutation discovered in Parkinson’s disease

Researchers have identified the first case of a patient with Parkinson’s disease carrying a mutation in the ACMSD gene…

mutation

Mutations in the human genome may be responsible for many diseases. In the case of Parkinson’s disease (PD), five locations have been the subject of recent attention. Variants of one of these locations, ACMSD (amino-carboxymuconate semialdehyde decarboxylase), may be implicated in PD, but until now, no mutations in ACMSD have been found in any PD patients.

Researchers found identified a unique mutation in a 74-year-old man with PD. This mutation is not found in the neurologically normal population and may be the first indication that rare variants in ACMSD alone might increase the risk of PD.

The novel ACMSD mutation was identified during a genetic screening study of 62 PD patients on the Mediterranean island of Menorca, which were matched with 192 ethnicity-matched neurologically normal individuals with no family history of PD.

Genetic variants found in these individuals were checked against various databases to identify normal variations observed in other populations.

 

Reserve your FREE place

 


Reduce preclinical failures with smarter off-target profiling

24 September 2025 | 15:00PM BST | FREE Webinar

Join this webinar to hear from Dr Emilie Desfosses as she shares insights into how in vitro and in silico methods can support more informed, human-relevant safety decisions -especially as ethical and regulatory changes continue to reshape preclinical research.

What you’ll learn:

  • Approaches for prioritizing follow-up studies and refining risk mitigation strategies
  • How to interpret hit profiles from binding and functional assays
  • Strategies for identifying organ systems at risk based on target activity modulation
  • How to use visualization tools to assess safety margins and compare compound profiles

Register Now – It’s Free!

 

While researchers found mutations already associated with PD, they discovered one novel mutation in the ACMSD gene in a single patient with no family history of PD and none of the known PD-related mutations found in other populations.

“Our findings suggest that a new mutation in the ACMSD gene could be a risk factor for PD. It could lead to the identification of more cases with genetic PD, both sporadic and familial, and consequently to better management of the patient. The ACMSD gene was previously associated with the risk for PD by various genome-wide association studies,” explained lead investigator Dr Coro Paisán-Ruiz, Department of Neurology, and Departments of Psychiatry and Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.

The ACMSD gene encodes for an enzyme in the kynurenine pathway, amino-carboxymuconate semialdehyde decarboxylase, involved in the metabolism of tryptophan. Some metabolites of the kynurenine pathway are known to play an important role in the central nervous system in both health and disease states.

Specifically, ACMSD activity results in less accumulation of quinolinic acid which is a molecule known to have neurotoxic properties. Not only does quinolinic acid cause excitotoxicity, but it can also directly activate the immune cells of the brain, i.e. microglia, and thereby trigger inflammation. Therefore, there is a good pathobiological rationale for why reduced levels of functional ACMSD can result in the type of neurodegeneration seen in PD brains.

“The results of the current study are of great interest because the identification of a new mutation linked to the disease could lead us to a better understanding of the disease and, eventually, to the development of new therapeutic strategies,” explained Dr Paisán-Ruiz.

Related topics
,

Related conditions

Related organisations

Related people

Leave a Reply

Your email address will not be published. Required fields are marked *